Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies - AstraZeneca (NASDAQ:AZN)

Benzinga

Center

High Factuality

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies - AstraZeneca (NASDAQ:AZN)

CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (NASDAQ:AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. Under the terms of the…